Anniversary Timeline

25th Years of Innovation


2020: First vaccine for the prevention of COVID-19 to receive conditional marketing authorization from the European Medicines Agency: COMIRNATY® (BNT162b2/Pfizer-BioNTech COVID-19 vaccine)

Nominated by: Pfizer Organisations in nomination: Pfizer, BioNTech     In March 2020, the WHO declared COVID-19 a pandemic. At “lightspeed,” Pfizer collaborated with BioNTech, a..Read More


2020: First large scale application of AI to protein structure determination: AlfaFold

Nominated by: UK BioIndustry Association  Organisation in nomination: DeepMind   An artificial intelligence (AI) network developed by Google AI offshoot DeepMind made a gargantuan leap in solving..Read More


2019: Large scale microbial production of next generation, zero-calorie, non-artificial EVERSWEET™ Stevia sweetener

Nominated by: DSM Organisation in nomination: DSM, Cargill Most people consume too many calories that originate from sugar, increasing the risk of being overweight or developing..Read More


2018: First CAR T cell therapy approved in the US for adult patients with DLBCL and amongst the first approved in Europe

Nominated by: Kite (a Gilead Company)    Organisations in nomination: Kite (a Gilead Company) Non-Hodgkin lymphoma (NHL) can occur at any age, and accounts for an..Read More


2018: European “1+ Million Genomes” Initiative launched

Nominated by: Voisin Consulting Life Sciences The European “1+ Million Genomes” Initiative builds from the achievements of the Human Genome Project and aims to have at..Read More


2018: Autologous CAR-T cell therapy Kymriah – unique to each patient. First EC approval for two indications (pALL and DLBCL)

Nominated by: Novartis Organisations in nomination: Novartis Acute lymphoblastic leukaemia (ALL) is a type of cancer that affects white blood cells. It progresses quickly and aggressively..Read More


2017: First Radioligand therapy (RLT) approved in Europe for the treatment of gastroenteropancreatic neuroendocrine tumours – Lutathera®

Nominated by: Novartis Organisations in nomination: Novartis Gastroenteropancreatic neuroendocrine tumours are a rare type of cancer that can form in the pancreas or in other parts..Read More


2016: First curative gene therapy for ADA-SCID approved for infants

Nominated by: Federchimica Assobiotec Organisation in nomination: GlaxoSmithKline (GSK), currently moved to Orchard Therapeutics, Telethon Foundation (Telethon), l’IRCCS San Raffaele Hospital (SRH) Italy and Molecular Medicine SpA..Read More


2016: World’s first industrial scale plant for production of butanediol (1,4 BDO) from renewable materials via biosynthesis (fermentation from micro-organisms)

Nominated by: Federchimica Assobiotec  Organisation in nomination: Novamont (Italy) 1,4, Butanediol is a chemical intermediate used for a wide range of applications, including industrial processes (as..Read More


Improved food safety through asparaginase produced via genetically modified micro-organisms: reduced acrylamide in cooked food

Nominated by: DSM Organisation in nomination: DSM and Novozymes     Acrylamide can arise during the cooking process of foods via reaction of the amino acid asparagine and..Read More

  • Olon Group
  • Inscripta Inc.
  • Abolis
  • Health & Life Sciences cluster Bulgaria
  • EV Biotech
  • Mabdesign
  • Remilk
  • Bon Vivant
  • Phytolon
  • Trinomab
  • Freget Glaser & Associes
  • The Union of Biotechnological Companies BioForum
  • SenseUp GmbH
  • Bioeconomy for Change
  • Royal DSM
  • ZeClinics


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!



Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!

Become a member